4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5-hydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-7-(phosphonooxy)- manufacturers
- TP1287
-
- $1670.00
-
2026-07-27
- CAS:2044686-42-0
- Purity:
- Supply Ability: 10g
|
| | 4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5-hydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-7-(phosphonooxy)- Basic information |
| | 4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5-hydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-7-(phosphonooxy)- Chemical Properties |
| Boiling point | 717.1±70.0 °C(Predicted) | | density | 1.576±0.06 g/cm3(Predicted) | | pka | 1.58±0.10(Predicted) | | form | Solid | | color | Light yellow to yellow |
| | 4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5-hydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-7-(phosphonooxy)- Usage And Synthesis |
| Uses | TP-1287, a prodrug of Alvocidib (HY-10005), is an orally active CDK9 inhibitor[1]. | | in vivo | TP-1287 (2.5-15 mg/kg; oral) suppresses tumor growth in models of multiple myeloma[1].
TP-1287 is highly soluble over a broader pH range than Alvocidib (HY-10005) and is efficiently metabolized to the parent compound in vivo, following oral administration[2]. | Animal Model: | RPMI-8226 xenograft model for multiple myeloma[1] | | Dosage: | 2.5, 7.5, and 15 mg/kg | | Administration: | Oral | | Result: | Achieved tumor growth inhibition (%TGI) of 56.0, 76.6, and 93.9% at doses of 2.5, 7.5, and 15 mg/kg, respectively. |
| | IC 50 | CDK9 | | References | [1] Tyagi E, et al. The Oral CDK9 Inhibitor, TP-1287, Is Active in Non-Clinical Models of Multiple Myeloma. Blood, 2018, 132: 3269.
[2] Kim W, et al. TP-1287, an oral prodrug of the cyclin-dependent kinase-9 inhibitor alvocidib. Cancer Research, 2017, 77(13_Supplement): 5133-5133. |
| | 4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5-hydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-7-(phosphonooxy)- Preparation Products And Raw materials |
|